Flat-Line Orkla Digests Middle East Costs While US Staples Harvest Tariff Refunds

Q2 volume mix -1.3%, 'revenue declined' tops the keyword chart, and the CFO is blunt: 'we are not satisfied.'

ORK.OL · Earnings Call · 2026-08-20

A flat quarter, frankly admitted

With CEO Nils Selte traveling, it fell to CFO Arve Regland to deliver Orkla's Q2 2026 report — and he opened with a rare, blunt admission:

Overall, we are not satisfied with these results.
Arve Regland, Chief Financial Officer · 2026-08-20

The numbers justify the tone. Consolidated organic top line was flat, volume mix fell 1.3%, and adjusted EBIT grew just 2.5% — helped almost entirely by Jotun. Reported revenue actually dropped 5%, though most of that was foreign-exchange translation (negative currency effects "continue to weigh"). The company's revenue declined — a phrase that has never led this company's transcript before — now tops the keyword chart with a sharp momentum spike, and the decliners list confirms the mood: Orkla Health fell hardest as its turnaround stalls.

The Easter echo and the "look at H1" answer

The single largest distortion was Easter timing: a positive phasing effect in Q1 reversed into a headwind in Q2, hitting Foods, Snacks, and Food Ingredients. When an analyst pressed for a quantification, Regland declined and instead directed everyone to the half-year view: “it's really better to look at the first half numbers because then you eliminate the Easter effects” — Arve Regland, Chief Financial Officer · 2026-08-20. It is a repeated refrain — in May he warned “if it's a support effect on Q1, it has the opposite effect in Q2” — Arve Regland, CFO · 2026-05-20 — and the underlying message is that H1 organic growth still sits below the strategy-period ambition. The Easter effects are transitory, but volume growth is the structural question the CFO keeps returning to.

The Middle East cost overhang

The bigger overhang is cost. At the start of the year, the CEO was relatively sanguine:

we don't expect the same huge effect as we saw from the post-pandemic inflation
Nils Selte, President and CEO · 2026-05-20

. This quarter the tone is more cautious. Orkla's exposure is concentrated in Jotun, which delivered another strong quarter — underlying revenue +11%, underlying operating profit +21%, Orkla's share up 17% to NOK 494 million — despite raw material prices rising "significantly" and "less than anticipated" at the Q1 outlook. But the CFO warned that margin pressure is coming: margins “do not yet fully reflect the increase in raw material prices” — Arve Regland, Chief Financial Officer · 2026-08-20, and Jotun's “business units within the war affected markets had a flat underlying sales development and a 2% increase in underlying operating profit” — Arve Regland, Chief Financial Officer · 2026-08-20. The persistent Middle East conflict keyword remains the unquantifiable variable: "both the timing and the magnitude remain difficult to quantify."

The tape's other story: no tariff refund here

The most striking contrast this week is not within Orkla — it is against the tape. The global earnings backdrop (20263) is dominated by Net tariff refunds and IEEPA refund language: Walmart, Target, TJX, Lowe's, Ross, Home Depot, and Coty all booked tariff-refund benefits in this very reporting window. Orkla sits entirely outside that fiscal tailwind. Its cost pressure comes from the Middle East — energy, freight, packaging — with no offsetting policy kick. US consumer staples are harvesting an accounting gift while the Nordic packaged-foods giant absorbs geopolitical input-cost inflation. It is a clean illustration of how different regions of the consumer-defensive complex are being driven by completely different forces this quarter.

Deploying capital while growth stalls

Against the flat organic picture, Orkla kept executing on M&A: the Candy Group acquisition for Orkla Snacks (BUBS expansion now in ~60,000 US stores via Mount Franklin Foods) and a 40% stake in Go-Tan Group for sauces. The mitigating actions theme is also live — most clearly in Food Ingredients, where lower volumes met a cost base "too high relative to activity levels." The CFO said the SG&A-focused measures will not bite until next year: “I wouldn't expect them to have a significant impact in the very short term, but more on the — a bit longer term, meaning from next year and onwards” — Arve Regland, Chief Financial Officer · 2026-08-20. Meanwhile Orkla Health, the most persistent laggard, will carry factory-closure drag "through the end of 2027" — echoing the Q1 line that “they are obviously lagging the plans” — Arve Regland, CFO · 2026-05-20. So Q2 is a holding-pattern quarter: capital still being deployed into growth categories, but the income statement flat-lining. The December 1 Capital Markets Day will test whether management can frame a credible path back to the 10.5–11% margin band and stronger volume growth.